arrow
D

David S. Siegel

hackensack university medical center
H指数:82
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consolidation Therapy with Checkpoint Inhibitors after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma

自体造血细胞移植后高危多发性骨髓瘤和淋巴瘤患者的检查点抑制剂巩固治疗

2026-05-140
PRE
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience

复发难治性多发性骨髓瘤患者接受商业化双特异性T细胞衔接抗体治疗的真实世界结局:一项单中心经验

2025-11-010
PRE
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia

B cell maturation antigen 是急性髓系白血病的免疫治疗新靶点

2025-10-260
OAAI
A phase IIb study of selinexor in combination with daratumumab inpatients with daratumumab-refractory multiple myeloma

Selinexor与daratumumab联合治疗daratumumab耐药多发性骨髓瘤的IIb期研究

2025-10-010
OAAI
Digital PCR Assay Utilizing In-Droplet Methylation-Sensitive Digestion for Estimation of Fetal cfDNA From Plasma

利用液滴内甲基化敏感性消化进行血浆胎儿cfDNA估计的数字PCR检测

2025-03-160
OAAI
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

雷帕霉素抵抗性多克隆Th1/Tc1细胞疗法(RAPA-201)安全地诱导复发、难治性多发性骨髓瘤的疾病缓解。

2025-01-280
OA
Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

真实世界中Ciltacabtagene autoleucel与Idecabtagene vicleucel治疗复发/难治性多发性骨髓瘤的疗效与安全性比较:一项回顾性意向性治疗分析

BLOOD
IF23.1
2024-11-050
PRE
Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

真实世界结局:talquetamab(一种T细胞重定向的GPRC5D双特异性抗体)——一项针对复发/难治性多发性骨髓瘤(RRMM)的单中心经验

BLOOD
IF23.1
2024-11-051
PRE
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Idecabtagene Vicleucel (Ide-cel) 在对新诊断多发性骨髓瘤(NDMM)且对一线自体干细胞移植(ASCT)反应不足的患者(Pts)中的研究:KarMMa-2研究队列2c的扩展随访

BLOOD
IF23.1
2024-11-050
PRE
A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

一项Selinexor与Pomalidomide联合治疗Pomalidomide难治性多发性骨髓瘤的2b期研究

BLOOD
IF23.1
2024-11-050
PRE
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

多发性骨髓瘤的综合分子谱分析可确定精细的拷贝数和表达亚型

2024-08-192
OAAI
Beyond detection: AI-based classification of breast cancer invasiveness using cellfree orphan non-coding RNAs
2024-03-220
PRE
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
2023-08-1745
OAAI
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience

多发性骨髓瘤BCMA嵌合抗原受体T细胞槽分配的伦理挑战: 多机构经验

2023-04-0138
OAAI